



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

November 30, 2023

Daniel Vitt
Chief Executive Officer
Immunic, Inc.
1200 Avenue of the Americas
Suite 200
New York, NY 10036

Re: Immunic, Inc.
Registration Statement on Form S-3
Filed November 22, 2023
File No. 333-275717

Dear Daniel Vitt:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Lauren Hamill at 303-844-1008 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Ilan Katz